Přihlásit se Zaregistrujte se zdarma

Dluh/Vlastní kapitál společnosti Interpace Biosciences Inc

Jaká je hodnota metriky Dluh/Vlastní kapitál společnosti Interpace Biosciences Inc?

Hodnota metriky Dluh/Vlastní kapitál společnosti Interpace Biosciences Inc je 2.05

Jaká je definice metriky Dluh/Vlastní kapitál?



Poměr dluhu k vlastnímu kapitálu (debt to equity ratio) udává podíl vlastního kapitálu a cizích zdrojů na financování majetku společnosti.

The debt to equity ratio is generally calculated by dividing debt by equity. The D/E ratio is also known as risk, gearing or leverage. The two components are often taken from the firm's balance sheet or statement of financial position (so-called book value), but the ratio may also be calculated using market values for both, if the company's debt and equity are publicly traded, or using a combination of book value for debt and market value for equity financially. Preferred stock can be considered part of debt or equity. Attributing preferred shares to one or the other is partially a subjective decision but will also take into account the specific features of the preferred shares. When used to calculate a company's financial leverage, the debt usually includes only the long-term debt.

Dluh/Vlastní kapitál společností v sektoru Health Care sektor na NASDAQ ve srovnání se společností Interpace Biosciences Inc

Čemu se věnuje společnost Interpace Biosciences Inc?

advancing patient care through molecular diagnostic testing. interpace diagnostics develops molecular diagnostic tests. our molecular diagnostic tests provide unparalleled accuracy and clarity to improve outcomes in patients facing a cancer diagnosis. you can be assured that all of the molecular tests we offer are driven by rigorous, validated science. we power the future of molecular diagnostics, delivering cutting-edge and much-needed mutational analysis that helps risk-stratify for thyroid, pancreatic, and other cancers to better inform treatment decisions. the unique molecular diagnostic tests we offer enable healthcare providers to avoid unnecessary surgeries and better assess the risk of cancer progression in their patients.

Firmy s metrikou dluh/vlastní kapitál podobnou společnosti Interpace Biosciences Inc